The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
(Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Companies argue they’re filling a need created by these miracle weight-loss drugs. But are they offering something of real ...
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
Consequently, food companies are rushing to reformulate products for protein lovers. That’s a category that includes both people taking the powerful new class of obesity drugs known as GLP-1s, who are ...
There are many reasons, but the most important is reduced reimbursement for prescription drugs. Most community pharmacies operate under a business model centered on dispensing medications that relies ...
For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results